Why Humacyte, Inc.’s vascular tissue platform is gaining attention in high-risk dialysis populations
Why Humacyte, Inc.’s ATEV is gaining traction in dialysis care. Explore clinical data, risks, and what comes next in vascular access innovation.
Pharma & Biotech
Pharma & Biotech
What ZORYVE cream’s infant indication means for non-steroidal eczema treatments
Can ZORYVE cream transform infant eczema care? Explore what this FDA filing means for non-steroidal treatment strategies today.
Pharma & Biotech
Why BioVie Inc.’s Phase 2 bezisterim data could shift the Parkinson’s disease treatment paradigm
Explore how BioVie Inc.’s bezisterim could reshape Parkinson’s treatment strategies ahead of Phase 2 data. Find out what it means for the industry.
Pharma & Biotech
Why Pacira BioSciences, Inc. is positioning EXPAREL as a cost-saving tool in Medicare surgery
Find out how Pacira BioSciences, Inc.’s EXPAREL data could reduce opioid use and surgical costs in Medicare patients.
Pharma & Biotech
Why the Veradermics hair loss trial is bigger than another aesthetics readout
Hair loss drugs are old, demand is huge, and Veradermics now faces the data test that could reset oral minoxidil’s commercial future.
Pharma & Biotech
Can Ascletis Pharma challenge injectable GLP-1 leaders with oral ASC30?
Oral GLP-1s promise convenience, but proof is still clinical. Ascletis’ ASC30 diabetes trial could test whether hype can meet HbA1c data.
Pharma & Biotech
Why Sun Pharma’s $11.75bn Organon acquisition could reshape specialty pharma
Sun Pharma gets global scale with Organon. The harder test is whether women’s health, biosimilars, and debt discipline can move together.
Pharma & Biotech
Can Brii Bio’s HBV rebound data move functional cure closer to clinical reality?
HBV cure hopes depend on durability, not just antigen loss. Brii Bio’s APASL data shifts attention to post-treatment control.
Pharma & Biotech
Arrowhead’s plozasiran clears CHMP: what a positive opinion for FCS means for siRNA’s regulatory arc in Europe
Plozasiran clears CHMP but the real test is reimbursement. Europe's HTA bodies will now decide whether clinical FCS diagnosis is enough.
Pharma & Biotech
Merck’s Terns deal clears antitrust hurdle as TERN-701 becomes bigger oncology test
Merck cleared one deal hurdle. TERN-701 still has to prove whether chronic myeloid leukemia can justify a $6.7 billion bet.